Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced the commercial launch in Europe of the ...

Medtronic's diabetes spin-off MiniMed seeks $784M IPO at $7.86B valuation after six quarters of double-digit growth in booming CGM market.

Medtronic on Tuesday priced a planned initial public offering for its MiniMed diabetes spinoff at up to $784 million. MiniMed ...

In an amendment to an SEC filing, Medtronic's Diabetes unit, MiniMed, today priced its planned initial public offering (IPO).

Feb 24 (Reuters) - Medtronic's MiniMed Group said on Tuesday it was aiming for a valuation of up to $7.86 billion in its initial public offering in the United States, advancing the medical device ...

Medtronic's MiniMed Group said on Tuesday it was targeting up to $7.86 billion valuation in its U.S. initial public offering, marking a step forward in the medical device maker's plan to separate its ...

Early clinical trials established the safety and feasibility of closed-loop insulin delivery, but the 2019 iDCL trial1 marked the first large, outpatient, randomised, controlled trial to show a ...

In combining the precision of the twiist insulin delivery system with the unmatched longevity of Eversense 365, Sequel and Senseonics are enhancing diabetes management by offering more tools to manage ...

Medtronic said today that the separation of its MiniMed Diabetes unit remains on track as it advances the MiniMed Flex system ...

Objective: To determine the feasibility of continuous glucose monitoring in the very low birthweight baby requiring intensive care, as these infants are known to be at high risk of abnormalities of ...

Real-world use of the MiniMed 780G (MM780G) system is associated with effective glycemic control on days when users do not administer bolus insulin, achieving a mean time in range of 70.9%. Real-world ...